LifeVantage (LFVN) investor relations material

Executive summary

• Q3 FY2026 net revenue was $43.7 million, down 25.2% year-over-year, mainly due to lower MindBody GLP-1 System sales, partially offset by LoveBiome acquisition sales.

• Net income for Q3 FY2026 was $1.4 million ($0.11 per diluted share), a 61% decrease from $3.5 million ($0.26 per share) in the prior year.

• Adjusted EBITDA was $3.2 million (7.3% of revenue), down from $6.4 million (11%) in the prior year.

• Active accounts declined 22% year-over-year, with notable decreases in both independent consultants and customers.

• Management remains focused on expense control, capital allocation, and share repurchases, with a new CEO appointed and a U.S. patent granted for Healthy Glow Essentials Stack.

Financial highlights

• Gross profit margin for Q3 FY2026 was 79.0%, down from 81.0% year-over-year, impacted by higher shipping, warehouse, and inventory obsolescence costs.

• Operating income was $1.7 million, down from $4.1 million in the prior year.

• Adjusted net income was $1.5 million ($0.12 per share), versus $3.5 million ($0.26 per share) prior year.

• Cash from operations for the first nine months was $5.5 million, down from $10.8 million year-over-year.

• Cash and equivalents at March 31, 2026, were $12.5 million, with no debt outstanding.

Outlook and guidance

• FY2026 revenue, adjusted EBITDA, and adjusted EPS expected near the lower end of prior guidance.

• Full-year commissions and incentive expense projected at approximately 42.5% of revenue.

• Effective tax rate for FY2026 expected to be 18%-20%.

• Management expects continued fluctuations in effective tax rate and gross margin due to discrete items and product mix.

• Ongoing focus on international expansion, product innovation, and integration of LoveBiome assets.